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Abstract The introduction and scale-up of new tools for the
diagnosis of Tuberculosis (TB) in developing countries has
the potential to make a huge difference to the lives of millions
of people living in poverty. To achieve this, policy makers
need the information to make the right decisions about which
new tools to implement and where in the diagnostic algorithm
to apply themmost effectively. These decisions are difficult as
the new tools are often expensive to implement and use, and
the health system and patient impacts uncertain, particularly in
developing countries where there is a high burden of TB. The
authors demonstrate that a discrete event simulation model
could play a significant part in improving and informing these
decisions. The feasibility of linking the discrete event simula-
tion to a dynamic epidemiology model is also explored in
order to take account of longer term impacts on the incidence
of TB. Results from two diagnostic districts in Tanzania are
used to illustrate how the approach could be used to improve
decisions.
Keywords Developing Countries . Simulation .
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1 Introduction
According to the World Health Organization (WHO) there
were 8.8 million new cases and 1.4 million deaths resulting
from Tuberculosis (TB) in 2010. TB is the archetypal dis-
ease of poverty and has highest incidence rates in the
countries of sub-Saharan Africa, where pulmonary TB
accounts for 81 % of all notified cases. It is estimated over
10 % of TB cases are Human Immunodeficiency Virus
(HIV) positive, with 82 % of these cases living in Africa
[1]. Highly cost-effective antibiotic treatment for TB is
readily available, however the failure to diagnose cases
rapidly means TB remains a major threat to public health
[2]. TB is an infectious airborne disease and the WHO
estimate that every individual left untreated infects a further
10 to 15 people every year [1]. Therefore, the delays in
diagnosis not only result in poor treatment outcomes at the
individual level, but also longer infectious periods resulting
in sustained transmission at the community level.
The standard approach for the diagnosis of pulmonary
TB relies on microscopic evaluation of sputum samples
collected from individuals suspected of having TB. The
process that a typical individual showing symptoms of TB
would need to follow in order to access diagnosis and
treatment is illustrated in a simplified flow diagram in
Fig. 1. Published research shows that in the developing
world this process presents a number of barriers to infected
individuals that limit its effectiveness [3–5]. A major barrier
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is the time spent (and therefore high cost relative to income
incurred) by the poor in accessing diagnosis even when the
consultation process and treatment itself are provided free of
charge. This is due to the high number of separate visits to
the diagnostic centre that are required (at least three) and the
distances that sick individuals need to travel usually on foot
to receive a TB diagnosis [3]. These factors lead to many
individuals either not starting the diagnostic process, or
starting but not completing diagnosis (diagnostic default)
or treatment (treatment default).
Efforts by organisations such as the Stop-TB partnership [2]
and the Foundation for Innovative New Diagnostics (FIND) to
stimulate innovation in the processes and technology of TB
diagnosis have resulted in the development of several innova-
tive diagnostic tools and improved algorithms [6–10]. Some of
these optimise existing technologies e.g. using updated micro-
scopes (light-emitting diode (LED) fluorescence microscopes
[6]), whilst others involve introducing new, innovative and
much more expensive technologies such as automated nucleic
acid amplification tests (aNAAT) [7, 10]. These tests identify
targeted nucleic acid sequences in the TB genome that can
provide results from sputum samples in less than two hours.
These new technologies can replace microscopy as the primary
tool for initial TB diagnosis, but involve retraining staff, sig-
nificant investment in equipment and expensive consumables
for each individual test.
WHO requires evidence to endorse any new diagnostic
tool or combinations of tools in order to formulate guide-
lines and recommendations [11]. The evidence required by
this process is generally presented in the form of systematic
reviews of accuracy or efficacy based on test or demonstra-
tion studies. These summarise the quality of evidence about
whether innovations can work based on observed sensitivity
and specificity. Evidence about whether they will actually
work or their likely impacts in different contexts is usually
lacking [12]. For example, different diagnostic strategies
could be more or less cost effective in settings with different
levels of HIV, drug resistance, or access to other health
facilities. We suggest that a more complete comparison of
the impacts of different diagnostic strategies is required by
policy makers within resourced constrained developing
countries if they are to successfully implement cost effective
solutions for their specific context [13]. Controlled trials to
compare all the available options in order to understand the
health system, patient, and transmission impacts of different
TB diagnostic tools are in reality impractical due to the wide
array of options and contexts. Therefore, a modelling ap-
proach is proposed that uses the data from current practice in
the context being considered, alongside the data from dem-
onstration trials of the new technologies from a different
context, to project the future impacts of changes in diagnos-
tic tool or algorithm. Once the model is developed it can
then be updated as new information from trials and current
practice becomes available. It can also be adapted through
data feeds and other inputs to model other contexts.
Here we use an original application of discrete event simu-
lation (DES) to model the health system for TB diagnosis and
treatment in developing countries. An application of the model
using data from Tanzania demonstrates how the approach can
enhance understanding and quantification of the impacts in
Fig. 1 TB diagnosis and
treatment flow diagram
240 I. Langley et al.
order to facilitate rational and improved decisions by policy
makers. The approach uses, as an example, the potential full
implementation of aNAAT (e.g. XpertMTB/RIF [6]) in district
TB laboratories in Tanzania to show that a flexible and infor-
mative model can be developed. Full implementation of
aNAAT is compared to the current technology - Ziehl Neelsen
(ZN) microscopy, optimised smear microscopy using LED
fluorescence microscopes, and partial implementation of
aNAAT for individuals who are HIV positive. The feasibility
of improving future, longer term predictions by taking account
of the impacts on TB incidence through a link to a disease
transmission model is also explored.
2 Method selection
A review of the questions that policy makers need to address
in order to decide which of the available diagnostic tools and
algorithms for a specific context to implement was undertak-
en. The results of this review were matched to a framework
proposed by Mann et al. [13] for creating a comprehensive
evidence base for TB diagnostics. The framework, called the
Impact Assessment Framework (IAF), is a systematic way of
compiling, and checking for completeness, the questions that
policy makers and researchers need to consider. Table 1 shows
the IAF populated by the key questions that the modelling
would need to address. In order to help answer all these
questions the model would require both a detailed operational
component, to understand patient and health system effects, as
well as a disease transmission component to understand
impacts on the community. This paper is primarily focused
on the operational component. In order to understand whether
a comprehensive modelling approach could be developed that
covered projections of TB incidence as well, a link to a disease
transmission model was also tested. The operational compo-
nent and the link to the disease transmission component
are discussed below.
2.1 Operational component
The operational component needed to model the movement of
patients and sputum samples through the health system in
order to understand the impacts of different diagnostic tools
and algorithms on patients and the health system. Such an
approach would highlight any bottlenecks in the diagnostic
process and enable potential remedies to be investigated. The
Table 1 Impact assessment framework –questions that the modelling should seek to address
Assessment layer Stakeholder
Patient Ministry of health Community
EFFICACY What is the increase in patients
diagnosed and cured?
How many more TB treatments required?
-How well does it work? Will it reduce wastage – (e.g.
reduce false positive results)?
EQUITY Do HIV+ patients benefit? Staff impacts?
-Who benefits? Will it benefit the poor?
Will MDR-TB patients benefit?
HEALTH SYSTEM Will it reduce patient visits and
waiting time?
Staffing numbers and utilisation?
-Operational Effects
How much quicker will patients
be treated?
How much will it affect running costs?
What is the effect on the number of
samples collected?
Will it overcome bottlenecks or just
move them on?
Where in the diagnostic algorithm should
the new test be placed?
SCALE-UP How many patients will benefit
if rolled out?
Where to start? What will the impact be on TB
incidence and prevalence?-Impacts of national roll-out How much will it cost?
Is it cost effective?
HORIZON SCANNING Will it mean more patients seek
diagnosis?
What if: new tests become available,
performance changes, targeted
differently, numbers increase/decrease?
Will it contribute to achieving the
2015/2050 millennium development
goals for TB?
-What else is coming along?
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chosen modelling software would require an interactive model
building capability which researchers could use without the
need for programming skills. The model would need to be
flexible to enable a number of different diagnostic scenarios
and contexts to be represented without major redevelopment.
Essential would be the ability to link to standard databases
holding input and output data, and a visual representation of
the modelled processes in order to improve engagement and
assist in validation with experts in Tanzania. All these features
made using a commercially available discrete event simu-
lation (DES) package an attractive proposition.
DES is used extensively in the developed world to model
processes within health systems, and other commercial and
public sector situations [14–17]. However, there is consid-
erably less published material on the use of DES in health
studies in developing countries. A number of different DES
simulation modelling tools could be used to model the
health systems as proposed. For this study the Witness
simulation package [18] was selected as it provided the
features necessary and was available within the institution
carrying out the research. The supplier licensing the soft-
ware agreed that national TB programmes within develop-
ing countries could have access to the developed model for
experimentation purposes at no cost.
2.2 Linked operational and disease transmission components
To understand the transmission impacts of different diagnostic
tools and algorithms a dynamic epidemiological component
would be required. This component would need to model at a
different level (national or large regional area) to the detailed
operational component (district) with key outputs being pro-
jections of incidence and prevalence of TB over many years.
Dynamic epidemiological models of TB transmission using
differential equations to solve are well established. They spec-
ify how a population is divided into mutually exclusive health
states and how the flow between states depends on the current
state of the system [19–23]. Incorporating a disease
transmission component within multiple district level DES
models would be possible, but would add complexity and be
time consuming in terms of development. It was therefore
decided to test a link to a disease transmission component
based on a differential equation model of the type discussed by
Murray and Solomon [20], but adapted to incorporate the health
system dynamics for the diagnostic tool being employed.
The link between the operational and disease transmission
components would be established by creating input and output
cells within the databases used by each individual component
that would be populated by data from the other component.
Figure 2 illustrates this link. This structure would also allow
each component to be developed independently by research-
ers in separate institutions and countries, with the links be-
tween them provided by Excel databases. The key parameter
that the operational component would source from the disease
transmission component would be TB incidence, and hence
the number of people seeking TB diagnosis. The disease
transmission component would source two parameters from
the operational component. These would be the proportion of
individuals seeking diagnosis that fail to complete this process
(diagnostic default rate) and the time it takes for individuals
from initially seeking diagnosis to completing diagnosis and
starting TB treatment. These parameters are critical to disease
transmission as they contribute to the time that individuals are
infectious with TB and therefore the number of people that
contract active TB. This study would show if such a link
would be a practical approach or whether the health system
and transmission elements of the model would need integrat-
ing into a single tool.
3 Model building
3.1 Model structure
A discrete event simulation of the health system using
Witness was developed that encompassed the patient
Fig. 2 Linked operational and
disease transmission
components
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pathways and the processes that sputum samples followed
as illustrated in Fig. 3. Theses processes followed the
WHO’s published guidelines [24, 25]. The patient pathway
started at the point where individuals with TB symptoms
arrived at the district TB diagnostic centre and continued
through diagnosis, to the completion of TB treatment. The
flow of sputum samples was modelled starting at sputum
collection from the patient in the diagnostic centre then
through each element of the laboratory services where test-
ing takes place and potential bottlenecks can occur. When
drug resistance was suspected, the transportation of samples
to the central TB reference laboratory (CTRL) and the
stages within drug sensitivity testing were modelled.
The key elements within the Witness DES model were
entities (representing patients, sputum samples, and trans-
port); activities (representing reception, sputum collection,
clinical consultation, X-ray, sample preparation, sample test-
ing, sample examination, treatment education, and drug
sensitivity testing); queues (representing prior buffers to
each activity, patient waiting areas, and the treatment
stages); and resources (representing clinicians, nurses, diag-
nostic centre and CTRL laboratory staff).
3.2 Input parameters
The main input parameters, probability distributions, and
data sources are shown in Table 2. The cost estimates are
in US dollars and are based on estimates provided by the
National TB and Leprosy Programme (NTLP) of Tanzania.
The costs for aNAAT are based on Xpert MTB/RIF hard-
ware and tests as negotiated by FIND [26]. The Xpert MTB/
RIF cost per test is based on the lowest prices quoted and
therefore assumes widespread implementation of the tech-
nology in the developing world (i.e. $10.72 per test which
requires global demand to exceed 3.7 million units). If this
high usage is not achieved, prices may be as much as $16.86
per test. For these reasons the results presented should be
treated as indicative of what the modelling approach can
deliver rather than definitive forecasts of future absolute
costs. The model is configured in such a way that alternative
costs for interventions can be evaluated and sensitivity
analysis conducted.
3.3 Patient pathways – individuals with suspected TB
Patients were categorised when they entered the simulation
as either HIV positive or HIV negative and as new suspects
or retreatment cases. Retreatment cases have previously
been treated for TB, but return with the same symptoms
and therefore with a higher probability of being positive for
TB and multiple drug resistant TB (MDR-TB). Retreatment
cases start TB treatment before all the drug sensitivity
results are available due to the life threatening nature of
their condition.
Multiple visits by each new patient to the diagnostic
centre were modelled. The number of visits for each patient
was dependent on a number of factors: the diagnostic test
being modelled (note: sputum smear microscopy requires
two sputum samples collected on different days including a
morning sample in order to enhance the sensitivity for TB
diagnosis. ANAAT only requires a single sample); whether
the patient returns to the diagnostic centre when required or
becomes a diagnostic default; the backlog in the laboratory
that could lead to diagnosis not being available on the same
Individuals 
home
TB patients 
home
Sputum Collection, 
Consultations 
and Diagnosis
Treatment 
dispensed
& observed
Microscopy, culture and 
drug susceptibility testing
Central Reference Lab
(CTRL)
3. Return for further samples, 
diagnosis, or first treatment
2. Further sample required or not TB
8. Return for 
therapeutic 
monitoring
7. Return for next 
batch of medication
5. Start TB 
treatment
C. Drug resistance suspected,
 Transport samples to CTRL
1. Individual becomes sick with TB symptoms 
and is referred to diagnostic centre
9. Continuation 
of treatment
D. Results
6. Return home
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using ZN or LED 
Microscopy and/or
automated Nucleic Acid
Amplification tests (aNAAT) 
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education 
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Patients being treated for TB
Dash Lines --------------
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Fig. 3 Schematic of patient and
sputum sample pathways
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Table 2 Main input parameters to DES
Input parameter Description Source
Processing Times
Diagnostic Centre process times Duration of activities within the diagnostic centre
for reception, sputum collection, and clinical
consultations.
Estimated by management in Tanzania from
observations within diagnostic centres.
District and Central laboratory process times Duration of and batching process for microscopy,
culture, and drug sensitivity testing.
WHO Global Laboratory Initiative guidelines.
Processing times for aNAAT The preparation and processing times for aNAAT
based on Xpert MTB/RIF.
Manufacturer’s instructions – Cepheid.
Patient Data
Proportion of smears testing positive % of samples when tested by microscopy result
in a positive TB test.
Diagnostic centre laboratory records.
TB cases per year Number of smear positive and smear negative
TB cases diagnosed by district.
National TB and Leprosy Programme (NTLP)
report 2010.
Number of new patients seeking diagnosis The number and the arrival rate of individuals
seeking diagnosis.
Mean daily numbers calculated from NTLP
reports and sampled from Poisson distribution.
Arrival time of patients The time during the day that the patient arrives at
the diagnostic centre
Sampled from a user defined distribution that
peaks at 45 min into the working day with all
patients arriving by noon.
Proportion of TB cases HIV positive % TB cases that are identified as HIV+. NTLP annual report 2010
Retreatment TB Cases per year Number of retreatment cases in a diagnostic district. NTLP annual report 2010
Return Probability The probability that an individual returns to the
diagnostic centre for the next stage of the
diagnostic process.
Published research [5]
Drug resistance levels Proportion of TB cases that are drug resistant. NTLP annual report 2010
Staffing availability
Staffing in diagnostic district Number of laboratory and clinical staff by diagnostic
district. Shift patterns.
Diagnostic centre management
Diagnostic test Accuracy
Accuracy of ZN Microscopy. Sensitivity and specificity of ZN Microscopy for TB
in sputum samples.
Published research [30]
Accuracy of X-ray and clinical judgement. Sensitivity and specificity of clinical judgement after
smear negative result.
Published research [28]
Accuracy of optimised smear microscopy Sensitivity and specificity of LED fluorescence
microscopy.
WHO policy statement – Fluor-escent light-
emitting diode microscopy for diagnosis
of TB.
Accuracy of Xpert MTB/RIF Sensitivity and specificity of Xpert MTB/RIF in
identifying TB from sputum samples.
WHO policy statement [11]
X-ray usage % of smear negative TB suspects where an X-ray
is requested.
Estimated by management in NTLP in Tanzania.
Proportion of aNAAT tests that give no
result
Level of retesting required for Xpert MTB/RIF Manufacturers data – Cepheid
No. of sputum tests required per suspect The number of sputum samples required for each
type of test.
NTLP Tanzania
Financial Data
Health System cost data Cost data for staff and drugs for the treatment of TB. NTLP Tanzania
ZN, LED, X-ray and aNAAT cost Cost per test and investment cost of new technology. NTLP in Tanzania and FIND [26]
Disability-Adjusted Life Years (DALY’s) Life expectancy and disability weights for TB and HIV WHO Country statistics [33]
Treatment Data
Treatment outcomes Proportion of TB cases treated that fall into the WHO
categories of cure, fail, treatment default, death,
transfer out.
NTLP annual report 2010
Treatment times Times for stages of treatment. WHO TB treatment guidelines [25].
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day as final sputum sample collection; the time the patient
was willing to wait in the diagnostic centre for results;
whether the initial test result was positive; whether X-ray
was required following a negative sputum test; and whether
TB treatment would be required (note: if the individual
completes diagnosis, a sputum smear positive test result
leads to the initiation of TB treatment, called a Smear
Positive TB case. A sputum smear negative test result leads
to the initiation of TB treatment if the clinician believes
mycobacterium tuberculosis is the likely cause of illness,
called a Smear Negative TB case. Smear Negative TB
diagnoses will usually follow further testing using X-ray
and are particularly common where there is high HIV prev-
alence such as in Tanzania [27, 28]).
3.4 Patient pathways – individuals being treated for TB
Once TB has been diagnosed a further visit to the diagnostic
centre was modelled to represent the patient’s visit with a
friend or a member of their family to receive the first batch
of medication and for treatment education (note: this process
is part of what is known as DOT- Direct Observation of
Treatment. DOT is an approach often used for TB treatment.
Patients are observed daily taking their medication by a
health care worker, friend, or relative to facilitate comple-
tion of the full course of treatment).
Patients were modelled returning to the diagnostic centre
during treatment for sputum smear microscopy testing after 2,
5, and 6 months of treatment. If the test was positive further
testing for drug resistance was modelled. If drug resistance
was detected the model represented these patients as being
diagnosed with MDR-TB by recording this as an outcome of
treatment (note: treatment for MDR-TB takes 2 years to
complete rather than the 6 m taken for drug sensitive TB. In
Tanzania and much of the developing world MDR-TB cur-
rently represents less than 0.5 % of new TB cases). The other
treatment outcomes recorded for patients in the model were
successful treatment completion; failed treatment (i.e. not
cured); or treatment default [25]. Treatment default included
patients that die, transfer to another centre, or just do not return
for tests and medication during treatment.
3.5 Sputum sample pathways
Sputum samples were modelled being collected in the diag-
nostic centre from individuals suspected of having TB and
individuals undergoing treatment for TB. Samples followed a
pathway through the district laboratory depending on the
patient characteristics, diagnostic technique, and diagnostic
algorithm being modelled. There were two very different
types of diagnostic test that were simulated. These were
microscopy tests which are very labour intensive, and aNAAT
which uses machines that can be of varying capacity.
These were therefore modelled separately with control logic
defining which test process would be used for which patient
sample. This logic enabled a number of different diagnostic
algorithms to be evaluated. Samples were modelled being
prepared and undergoing testing in the laboratory. This was
followed by the examination of the test result. If the test was
positive a proportion of samples from individuals suspected of
having TB and all the samples from individuals being treated
for TB were modelled being sent to the CTRL for drug
sensitivity testing (note: drug sensitivity testing can take up
to 3 months to complete). In the CTRL samples were modelled
being examined through microscopy, culture, and drug sensi-
tivity testing.
3.6 Outputs
The outputs from the model were designed to match the
requirements that WHO specify for randomised controlled
trials of new TB diagnostic technology [29]. These outputs
included the laboratory performance, patient diagnosis sta-
tistics, and patient treatment outcomes. This information
was copied to an Excel spreadsheet for further analysis
including calculation of the incremental cost effectiveness
ratios (ICER). In addition the diagnostic default rate and the
mean time for patients to receive diagnosis were copied to
an Excel file to provide the input data required for the linked
dynamic epidemiological model.
4 Model validation and experimentation
The DES model was validated in two ways. Firstly by work-
ing with experienced experts from Tanzania, Malawi, and the
Liverpool School of Tropical Medicine to ensure the input
parameters, and control logic were working as expected. This
involved using the visual display and running through scenar-
ios showing the patient and sample flows. An example of a
Witness screen layout for a diagnostic laboratory is shown in
Fig. 4. In addition, the model was validated by running for 11
simulated years with input parameters set to mimic the current
diagnostic strategies in operation in two diagnostic centres in
Tanzania. The two centres were chosen by the NTLP of
Tanzania as information was readily available, and different
microscopy techniques (ZN and LED)were used at the time of
data collection. One centre was from an urban area in Dar es
Salaam and the other from a more rural centre in the region of
Kilimanjaro. The outputs from the model were validated
against the reported results for 2009/2010. A summary from
this validation is shown in Table 3.
Experimentation using the DES was conducted to evaluate
four example diagnostic algorithms for TB (see Table 4) in the
diagnostic centres above. Each algorithm included a different
combination of diagnostic tests applied at the different stages
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of the TB diagnosis and treatment monitoring process. Option
C, which involves a modified algorithm, was added following
initial results from the modelling as the NTLP were concerned
about the costs of the full roll-out of aNAAT (Option B). The
model was run for 11 simulated years for each TB diagnostic
option being investigated. 11 years was chosen to allow 1 year
for initialisation of the model and then 10 years in order to
facilitate the calculation of confidence limits for the outputs.
To test the linkage of the DES with a dynamic epide-
miological model, the DES was run for 2 years (first
year for initialisation) based on current demand for TB
diagnostic services. The diagnostic default rate and the
mean time it took for individuals from initially seeking
diagnosis to starting appropriate treatment in the second
year was exported to an Excel file. This file was then used as
input into the epidemiological model. The epidemiological
model was then run for 1 year and a forecast of TB incidence
produced. This forecast was then used to modify the demand
for TB diagnostic services used as an input parameter to the
DES. The DES was then run for 1 further year and the
diagnostic default rate and the mean time to receive diagnosis
exported. These parameters were then fed into the epidemio-
logical model which projected TB incidence for a further year.
This process was repeated until 11 years had been modelled.
This whole process was repeated twice to model two diagnos-
tic strategies with distinctly different diagnostic default rates,
test sensitivities, and laboratory test times. This design enabled
the linked approach to be tested and example outputs produced
that could indicate the impact of changes in diagnostic perfor-
mance on TB incidence and prevalence.
Fig. 4 Witness screen view for
diagnostic laboratory
Table 3 Validation data
Area Current diagnostic technology Means and 95 %
confidence limits
Smear + ve
TB p.a.
Smear –ve
TB p.a.
Re-treatment
TB p.a.
HIV + New
Cases p.a.
Dar es Salaam (Urban) ZN Microscopy Observed 2009/2010 560 450 93 403
Modelled Mean 561.8 445.9 88.6 402.7
Lower Limit 545.2 434.3 82.5 390.6
Upper Limit 578.4 457.5 94.7 414.8
Kilimanjaro (Rural) LED Fluorescence Microscopy Observed 2009/2010 255 64 91 134
Modelled Mean 259.6 60.3 91.8 130.9
Lower Limit 249.5 55.4 86.0 122.5
Upper Limit 269.7 65.2 97.6 139.3
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5 Experimental results and evaluation
5.1 Simulation results based on a large diagnostic centre
in Dar es Salaam
Detailed results based on the simulation runs for the large
diagnostic centre in Dar es Salaam are shown in Table 5. This
table includes a ‘patient success rate’ which is defined as the
proportion of individuals with TB disease who seek diagnosis
and are cured. This factor takes into account not only whether
patients are put on treatment, but whether they successfully
complete treatment and whether they were correctly diag-
nosed in the first place. The denominator is the number of
all individuals seeking diagnosis who have TB disease includ-
ing those missed by the diagnostic process.
Comparing the performance demonstrates that switching to
LED Fluorescence Microscopy (Option A) from ZN Micros-
copy (Base Case) for this example diagnostic centre would
reduce the time to start treatment (−9 %). This leads to a
positive effect on reducing the proportion of diagnostic
defaults (−1.8%). An increase in the number of smear positive
cases detected (+108 per year) is almost fully offset by a
reduction in the number of smear negative cases (− 91 per
year). This means there is no significant increase in the num-
ber of patients started on TB treatment. However, a reduction
in the number of individuals incorrectly put on TB treatment
(false positives −2.8 %) as a result of smear negative clinical
diagnosis, results in a significant increase in the number of
patients cured (+5.0 %). This takes the patient success rate to
nearly 70 %. This is achieved with minimal increase in run-
ning costs for a low investment of around $2,300.
A full rollout of aNAAT (Option B) for diagnosis has a
greater impact. Comparing full aNAAT rollout using Xpert
MTB/RIF with ZN Microscopy (the base case) shows a
large reduction in the time to start treatment from a mean
of 24.8 days to 15.0 days (−39 %) and mean patient visits
required from 6.0 to 3.7. These improvements result in a
reduction in the proportion of diagnostic defaults (−5.0 %).
An increase in the number of test positive cases detected
(+499 per year) is partly offset by a reduction in the number
of test negative cases (−393 per year). This leads to a
significant increase in the overall number of patients started
on TB treatment (+10.5 %) and reduces the false positive
rate (−5.6 %). An increase in the number of patients cured
by 15.8 % takes the patient success rate to over 77 %.
Because Xpert MTB/RIF detects resistance to one of the
key TB drugs (Rifampicin) at initial diagnosis; there is also
a significant increase in MDR-TB cases detected (+2.9 per
year). This leads to drug resistant cases starting on effective
treatment earlier. To achieve these results requires invest-
ment of $34,700 and a significant increase in running costs
of around $46,800 per year for this diagnostic centre.
The fourth option (Option C) looks at a lower cost imple-
mentation of aNAAT by targeting the new technology only at
HIV+ cases where it is known the incremental effect is more
significant as the base case technology has particularly low
sensitivity for HIV+ individuals suspected of having TB [30].
Compared to Option B this reduces the impact, but still
delivers significant improvements over the base case. A re-
duction in the time to start treatment from a mean of 24.8 days
to 18.6 days (−25%) andmean patient visits required from 6.0
to 3.8 has a positive effect on reducing the proportion of
diagnostic defaults (−5.0 %). An increase in the number of
test positive cases detected (+337 per year) is partly offset by a
reduction in the number of test negative cases (−258 per year).
This leads to a significant increase in the number of patients
started on TB treatment (+7.7 %) and reduces the false posi-
tive rate (−5.0 %). An increase in the number of patients cured
by around 10.8 % takes the patient success rate to 73.6 %. To
achieve this requires investment of $19,300 ($15,400 less than
full aNAAT rollout) and increased running costs of $25,600
per year ($21,200 per year less than full aNAAT rollout).
For this example diagnostic centre, the results in Table 5
show that all of the options can be delivered with no change
Table 4 TB diagnostic options
Option Name Primary diagnostic tool Drug Susceptibility Testing (DST) Treatment monitoring tool
Base case ZN Algorithm ZN Microscopy with 2 samples DST in CTRL only ZN Microscopy
A LED Algorithm LED Microscopy with 2 samples DST in CTRL only LED Fluorescence Microscopy
B aNAAT Full Algorithm Xpert MTB/RIF with 1 sample Xpert MTB/RIF in Diagnostic
Centre & DST in CTRL
LED Fluorescence Microscopy
C aNAAT Partial Algorithm Xpert MTB/RIF for HIV+ new cases
and all retreatment cases.
Xpert MTB/RIF in Diagnostic
Centre & DST in CTRL
LED Fluorescence Microscopy
with 1 sample
& LED Microscopy for other cases
with 2 samples
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in laboratory staffing levels. Staff utilization falls by be-
tween 31 % and 61 % depending on the new test employed.
A diagnostic centre of this size requires a minimum of 2
trained laboratory staff to cover for sickness, training, and
holiday. So, although laboratory staff utilization is reduced
by introducing the new aNAAT test, there is unlikely to be
any cost saving, however there is an opportunity for staff to
be employed in other non TB diagnosis activities.
5.2 Incremental cost effectiveness ratios (ICER)
In order for policy makers to decide which of the available
options to implement, they need to understand the costs
versus benefits of each option and to be able to compare
these to other potential demands on resources. Table 6
includes an illustrative example of an assessment of incre-
mental cost effectiveness ratios (ICER). These are based on
the incremental health system costs per ‘Disability adjusted
life year’ (DALY) averted, as defined by the WHO [31, 32].
The calculations use data on life expectancy and disability
weights from the WHO Global Health Observatory [33]. For
this analysis, incremental health system costs include both
the additional annual running costs (i.e. consumables, drugs,
staffing, X-rays, and equipment maintenance) and the in-
vestment costs (i.e. microscopes, aNAAT equipment, and
computer equipment) discounted over 5 years at 5 % per
Table 5 Results from health system model for a diagnostic centre in Dar es Salaam
Performance Difference to base case
Base Case ZN A LED Micro B aNAAT Full C aNAAT Part A LED
Micro
B
aNAAT
Full
C
aNAAT
Part
Diagnosis
Mean Time to
treatment (days)
24.8 (24.7–24.9) 22.5 (22.4–22.6) * 15.0 (14.9–15.1) * 18.6 (18.5–18.7) * −9 % −39 % −25 %
Mean No. of
visits/patient
6.0 (5.9–6.1) 4.5 (4.4–4.6) * 3.7 (3.6–3.7) * 3.8 (3.7–3.8) * −25 % −38 % −37 %
Test +ve TB case/yr 562 (545–578) 670 (648–691) * 1060 (1041–1079) * 898 (882–915) * +108 +499 +337
Test -ve TB case/yr 446 (434–458) 355 (343–367) * 53 (48–57) * 188 (178–197) * −91 −393 −258
Total TB treatment
cases/yr
1008 (988–1028) 1025 (1002–1048) 1113 (1093–1133) * 1086 (1068–1103) * 1.7 % 10.5 % 7.7 %
MDR-TB Cases/yr 3.7 (2.4–5.0) 3.5 (2.2–4.8) 6.6 (5.0–8.2) * 4.6 (3.1–6.1) −0.2 +2.9 +0.9
Samples/yr (,000’s) 14.3 14.2 9.1 12.1 −1 % −36 % −15 %
% Initial default 15.7 % (15.5–15.9) 13.9 % (13.6–14.2) * 10.7 % (10.5–11.0) * 10.7 % (10.5–10.9) * −1.8 % −5.0 % −5.0 %
Treatment
Patients Cured
p.a.a (95 % C.I.)
842 (827–858) 884 (866–902) * 975 (955–995) * 933 (917–948) * 5.0 % 15.8 % 10.8 %
False + Rate for TB 14.3 % 11.5 % 8.7 % 9.3 % −2.8 % −5.6 % −5.0 %
Staffing
No.lab staff 2 2 2 2 0 0 0
Utilization 79 % 48 % 18 % 37 % −31 % −61 % −42 %
Costs
Incremental
Cost/yr $k
(95 % C.I.)
95.2 (90.2–100.3) 95.3 (90.3–100.2) 142.0 (137.6–147.3) * 120.8 (115.4–126.2) * +0.0 +46.8 +25.6
Investment Cost $k 0.0 2.3 34.7 19.3 +2.3 +34.7 +19.3
Summary
Patient Successb 66.6 % (65.3–67.8) 69.5 % (68.0–70.9) * 77.2 % (75.6–78.8) * 73.6 % (72.4–74.9) * +2.9 % +10.6 % +7.1 %
95 % confidence limits for the means in brackets
* - significantly different from base case at 95 % level
a Patients cured excludes false positives who received treatment but had no TB disease
b Patient success is the % of individuals with TB that seek diagnosis and are cured
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annum (the period and rate have been chosen to represent a
cautious view on the resilience of the technology in an
African setting). Summary results from the modelling are pre-
sented for both the diagnostic centre in Dar es Salaam and for
the more rural setting in the Kilimanjaro area where the base
case is LED fluorescence rather than ZN microscopy. These
results are indicative and suggest the ICER based on DALY’s
averted is minimal for LEDFluorescencemicroscopy, but more
significant for the aNAAT strategies and therefore needs to be
compared to other potential interventions in the health service
in Tanzania before progressing. The ICER could also be com-
pared to a country specific willingness to pay threshold such as
Gross Domestic Product (GDP) per capita or other alternative
thresholds as discussed in Shillcutt, et al. [34]. In this illustra-
tive analysis a low threshold of $150 has been used as proposed
by the World Bank for low income countries like Tanzania
[35]. With a threshold of $150 per DALY averted all these
interventions on their own would be considered cost effective.
Sensitivity analysis on the cost per test in Table 6 shows even
when costs per test rises to $16.86 these interventions fall well
below a ceiling of $150 per DALYaverted.
5.3 Deciding between potential combinations of interventions
ICER is a vital criterion that the Ministry of Health would
consider in making their decision, but it is not the only
criterion. For example, the sustainability of the intervention
would also be essential. To illustrate how the outputs from
the model might be used to decide between potential inter-
ventions, taking account of sustainability and the threshold
ICER, all relevant combinations of intervention from this
study for the two districts modelled have been listed in
Table 7. The interventions have been ranked by the impact
on health system costs from highest to lowest. The table
shows for each potential combination of interventions, the
projected impact on DALY’s, the incremental health system
costs, the ICER of the intervention compared to base case,
and the ICER compared to the next most effective interven-
tion that is less costly. Some combinations of intervention
are ineffective because there are other combinations that are
both more beneficial and less expensive e.g. implementation
of partial aNAAT at Dar es Salaam on its own (row 6) is
more expensive and less beneficial than combining LED in
Dar es Salaam and full aNAAT at Kilimanjaro (row 7).
Assuming an ICER threshold of $150 for an intervention
to be cost effective leads to some other interventions being
classified as incrementally ineffective. For example, the
ICER of implementing full aNAAT in Dar es Salaam com-
bined with partial aNAAT in Kilimanjaro (row 2), compared
to implementing partial aNAAT in Dar es Salaam combined
with full aNAAT in Kilimanjaro (row 3), is $362 and there-
fore is not incrementally effective. Table 7 also shows which
combinations of interventions provide best value for money
at differing levels of commitment to future incremental
spend. For example, if $30,000 per year is the sustainable
incremental level of spend, then the best combination of
interventions is LED microscopy in Dar es Salaam com-
bined with full aNAAT in Kilimanjaro (row 7).
5.4 Results from linking the DES with a dynamic
epidemiological model
Selected inputs and outputs from the test of linking the DES
with a dynamic epidemiological model are shown in Table 8.
Table 6 Illustrative summary results on incremental cost effectiveness ratios
Area Difference to base case A LED micro. B aNAAT full C aNAAT partial
Dar es Salaam (Urban) Incremental TB Patients cured per year 42 133 91
% increase in patients cured +5.0 % +15.8 % +10.8 %
Incremental DALY averted/year 399 (259–539) 1,220 (1011–1429) * 843 (655–1032) *
Incremental Health System costs/year ($k) 0.5 53.3 29.2
Incremental costs/DALY averted (ICER) ($) 1.2 (0.75–1.57) 43.6 (36.1–51.0) 34.5 (26.8–42.2)
Sensitivity of ICER to aNAAT cost per test $16.9
rather than $10.7
n/a 73.4 (60.8–85.9) 52.8 (41.0–64.6)
Kilimanjaro (Rural) Incremental TB Patients cured per year n/a 85 48
% increase in patients cured +25.3 % +14.4 %
Incremental DALY averted/year n/a 763 (663–864) * 434 (338–531) *
Incremental Health System costs/year ($k) n/a 26.0 18.8
Incremental costs/DALY averted (ICER) ($) n/a 34.0 (29.5–38.5) 43.1 (33.5–52.8)
Sensitivity of ICER to aNAAT cost per test $16.9
rather than $10.7
n/a 55.6 (48.3–62.9) 59.1 (46.0–72.3)
95 % confidence limits for the means in brackets
* - significantly different from base case at 95 % level
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These indicative results demonstrate that when the diag-
nostic strategy is changed there can be significant impact
on TB incidence. In the example in Table 8 two diagnos-
tic strategies are compared. Strategy 1: test sensitivity
50 % and mean time to receive diagnosis 4.3 days, com-
pared to Strategy 2: test sensitivity increased to 65 % and
mean time to receive diagnosis decreased to 1.7 days. The
result of such a change leads to a reduction in TB inci-
dence after 10 years of 6 %. These results illustrate how
transmission modelling can be linked to DES and enhance
understanding of impacts [36].
6 Discussion and further research
The results of the simulation demonstrate that DES can
provide useful projections of the effects on the health sys-
tem, running costs, and patient outcomes of alternative TB
Table 7 Ranked results for combined TB interventions in Dar es Salaam and Kilimanjaro
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Rank 
No. by 
cost 
(High- 
Low) 
Combination 
of 
interventions 
Incremental 
Health 
System   
Costs ($k) 
per year 
DALY’s 
averted 
per year 
ICER 
 to 
base 
case 
ICER(2) 
to the next 
effective 
intervention 
that is less 
costly 
Comment 
(ICER 
threshold of 
$150) 
1 
Dar es Salaam 
 - Full aNAAT  
Kilimanjaro 
 - Full aNAAT 
79.3 1,983 40.0 65.1
Cost 
effective 
$79.3k pa 
required  
2 
Dar es Salaam 
- Full aNAAT  
Kilimanjaro 
- Part. aNAAT 
72.1 1,654 43.6 361.8
Ineffective 
due to high  
ICER(2) 
3 
Dar es Salaam 
- Part. aNAAT  
Kilimanjaro 
- Full aNAAT 
54.7 1,606 34.0 63.5
Cost 
effective 
$54.7pa 
required 
4 
Dar es Salaam 
- Full aNAAT  
Kilimanjaro 
- Do Nothing 
53.3 1220 43.6 X
Ineffective 
due to no 
benefit over 
No.5 
5 
Dar es Salaam 
- Part. aNAAT  
Kilimanjaro 
- Part. aNAAT 
47.9 1,277 37.5 185.8
Ineffective 
due to high  
ICER(2) 
6 
Dar es Salaam 
- Part. aNAAT  
Kilimanjaro 
- Do Nothing 
29.1 843 34.5 X 
Ineffective 
due to no 
benefit over 
No.7 
7 
Dar es Salaam 
- LED Micro  
Kilimanjaro  
- Full aNAAT 
26.5 1,162 22.8 21.9
Cost 
effective 
$26.5pa 
required 
8 
Dar es Salaam  
- LED Micro  
Kilimanjaro  
- Part. aNAAT 
19.3 833 23.1 43.3
Cost 
effective 
$19.3pa 
required 
9 
Dar es Salaam 
- LED Micro  
Kilimanjaro  
- Do Nothing 
0.5 399 1.2 1.2 
Cost 
effective 
$0.5pa 
required 
diagnostic strategies in the diagnostic centres of Tanzania.
From these results it can be concluded that in the centre in
Dar es Salaam significant improvements in TB diagnosis can
be delivered through optimising sputum smear microscopy by
implementing LED Fluorescence microscopes. In this resource
constrained setting, an estimated 5.0 % increase in TB cures
could be delivered at very low investment. If more resources
are available, implementation of aNAATcan be a cost effective
approach in both Dar es Salaam and Kilimanjaro. The model
demonstrates that the benefit of aNAAT in the number of
patients cured is up to 15.8 % in Dar es Salaam and 25.3 %
in the Kilimanjaro area. These benefits accrue not just from an
increase in the number of patients started on TB treatment, but
also from earlier case detection, a reduced diagnostic default
rate, and a reduction in false positive diagnoses. Comparing
results between the 2 diagnostic centres indicates that the
benefits and cost effectiveness vary between settings. When
resources are scarce the results from the modelling can help
policy makers prioritise locations and the type of intervention.
6.1 Scale-up in Tanzania
Using the interactivity and flexibility of the DES modelling
approach makes it possible for TB policy makers to explore
future interventions and different contexts without major
model redevelopment. This utility has been recognised by
Table 8 Selected inputs/outputs from linking the DES with an epidemiological model
Modelling the impacts of new diagnostic tools for tuberculosis 251
Operational Component – Discrete Event Simulation
Input Output
Mean daily demand for 
diagnosis per centre
Mean days to receive diagnosis 
Year 1 Year 5 Year 10 Year 1 Year 5 Year 10
Strategy 1 15.0 13.5 12.2 4.3 4.1 4.2
Strategy 2
#
15.0 
(0%)
13.0 
(-4%)
11.5 
(-6%)
1.7 
(-60%)
1.7 
(-59%)
1.6 
(-61%)
Test sensitivity for TB Diagnostic default%
Year 1 Year 5 Year 10 Year 1 Year 5 Year 10
Strategy 1 50% 50% 50% 6.0 6.3 6.2
Strategy 2 65% 65% 65% 0.1 0.0 0.0 
Laboratory time per sample 
(minutes.)
Mean daily patients starting TB 
treatment per centre
Year 1 Year 5 Year 10 Year 1 Year 5 Year 10
Strategy 1 15 15 15 3.6 3.0 2.9
Strategy 2 
#
5
(-67%)
5 
(-67%)
5
(-67%)
4.2 
(+17%)
3.6
(+21%)
3.5 
(+20%) 
Disease Transmission Component – Dynamic Epidemiological Model
Output Input
TB Incidence (per 100,000) Diagnostic Default%
Year 1 Year 5 Year 10 Year 1 Year 5 Year 10
Strategy 1 113 103 93 6.0 6.3 6.2
Strategy 2 
#
112
(-1%)
100
(-3%)
87
(-6%)
0.1 0.0 0.0
TB Prevalence (per 100,000) Mean days to receive diagnosis 
Year 1 Year 5 Year 10 Year 1 Year 5 Year 10
Strategy 1 172 143 118 4.3 4.1 4.2
Strategy 2 
#
160 
(-7%)
122
(-15%)
99
(-16%)
1.7 
(-60%)
1.7 
(-59%)
1.6 
(-61%)
#  The percent is the relative difference comparing strategy 2 to strategy 1
Reprinted with permission of the International Union Against Tuberculosis and Lung Disease. 
Copyright © The Union [36]
policy makers in Tanzania who are now considering specific
sites and algorithms for trial of the new aNAAT technology.
These trial sites will be modelled and alternative diagnostic
algorithms investigated. In particular, a new lower cost
algorithm involving aNAATwill be explored. This interven-
tion will use aNAAT as an additional (rather than replace-
ment) tool to smear microscopy for new suspected TB cases.
Only suspects who are sputum smear negative and HIV
positive will be tested using aNAAT. The results of the
modelling will feed into the implementation trial and help
validate the approach, thereby improving its effectiveness
for future applications.
There are a number of further applications of the DES
model that are of interest and should be explored. The model
should be used to make an overall assessment of the impacts
of scale up of alternative algorithms using aNAAT across the
whole of Tanzania which should be designed to project the
impacts across the 168 diagnostic districts simultaneously
using the DES with periodic links to the disease transmis-
sion component. One approach being considered is the
identification and inclusion in a single model of a sample
of diagnostic facilities which would be representative of
districts with different capacity, HIV and TB prevalence.
These results could then be factored up proportionately to
represent the whole country.
Policy advisers in Tanzania have requested the ability to
be able to use the DES themselves to evaluate alternative
diagnostic strategies in the future. A pilot study in Tanzania
supported by the authors will demonstrate whether the mod-
els are sufficiently user friendly or whether further develop-
ment will be necessary. The policy advisers will be trained
to use the developed model to evaluate current TB diagnos-
tic technology against the new tools and alternative algo-
rithms for a sample of diagnostic districts. This will require
the developed model to be implemented on hardware in
Tanzania and data collected and loaded by Tanzanian staff
for each diagnostic district that is to be evaluated. Evalua-
tion of the impacts can then take place by local policy
advisors using the model. Development of the DES will
not be required by the staff in Tanzania.
6.2 Generic models and other applications
The DES has been developed as a flexible model based on
the knowledge of TB diagnostic processes in Tanzania and
Malawi. The flexibility incorporated allows many parame-
ters to be varied (Table 2) including patient demand and
profiles as well as alternative diagnostic tools and algo-
rithms for investigation. However, even though most devel-
oping countries follow the recommended TB diagnostic
algorithms of the World Health Organisation, it is likely that
some modifications would be required to represent some
other countries. These modifications are expected to be
principally in relation to the level of centralisation of TB
services. Centralisation affects patient pathways, and the
impact of the requirements for drug sensitivity testing, par-
ticularly for countries where multi drug resistant TB (MDR-
TB) is a greater burden (e.g. South Africa). Further research
is necessary to see whether the flexibility to cover these
differences can be incorporated into a generic model that
could then be used for TB diagnostics across the developing
world or whether a small suite of models is necessary to
cover each type of context.
The DES approach may also have benefits in helping
national TB programmes assess diagnostic tools used in
central reference facilities for diagnosis of MDR-TB. There
are many new tools now available including Xpert MTB/
RIF, Line Probe Assay, and liquid culture e.g. MGIT [37].
The authors plan to investigate the use of DES during
involvement in a pragmatic trial of these options in central
TB facilities in Brazil.
7 Conclusion
A health system modelling approach using a discrete-event
simulation (DES) tool can provide information to help policy
makers understand context-specific impacts in resource-
constrained settings and make decisions on TB diagnostic
tools. The DES can, and where possible should, be linked to
a disease transmission component to enhance predictions
and to provide outputs on important factors such as TB
incidence which will in turn impact health system and pa-
tient outcomes. A visual and interactive modelling tool ena-
bles national policy makers to assist in validation, identify
new strategies to investigate, and engage with the outputs.
Further research is needed to prove the approach across a
wider range of developing countries and then to actively use
the approach to assist in making the important decisions
about the options that leaders of national TB programmes
are currently considering. These decisions are urgent and
have the potential to make a highly significant and beneficial
impact on worldwide TB control in the coming years.
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